The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.
With strong clinical pipelines
and patent litigations, the market continues to experience significant changes.
Proton pump inhibitors (PPI) and antagonists of histamine H2 receptor have the
importance in current scenario of the market.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market/request-sample
Market Synopsis of Gastroesophageal Reflux Disease (GERD)
Therapeutics Market:
Upon loss of patent protection of
formerly leading branded drugs, generic molecules with low-price can ingest the
sales of the branded ones up to 90%. Rising number of companies being exposed
to price scrutiny associated with shift in the focus of government on the
promotion of consumer convenience will stimulate further reduction of drug
prices. Although market turnover is affected by the expiration of major patents
and the demand of drugs used to reduce acid, due to the increasing prevalence
of heartburn, is anticipated to increase in the upcoming years.
The devices of GERD serves as a
substitute for management of heartburn, because of low rate of success and
failure in clinical trials. Hence, very limited acceptance of devices of GERD
management contribute for the rising demand of drugs having acid neutralizing
property, as the major therapy approach.
Nevertheless, the advent of
devices which are minimally invasive to address anatomical defects are gaining
popularity coupled with supportive evidence from clinical data for performing
various procedures including trans oral fundoplication, which helps in preventing
reflux of non-acid and acid contents. The adoption of these devices have been
further reinforced in the U.S. in 2016 with the advent of a CPT code (43210)
which helps in facilitating reimbursement process.
Drug Type Insights
In 2016, market was dominated by
the antacids segment and is anticipated to keep its top position over the
forecast period. Most preferred first-line therapy for infrequent and mild
symptoms is antacids, as the therapy neutralize the secretion of gastric acid
immediately. Convenient OTC (over-the-counter) accessibility various forms such
as syrups, powders and tablets is accountable for the extreme adoption.
Moreover, the AHFS (American Hospital Formulary services), amongst other
countries, enlisted over 120 preparations too advocate.
In 2016, the second largest
segment was found to be PPIs as it is the most common medication prescription
type for the diseases such as heartburn. Generics inflow leading to the loss of
exclusiveness of popular drugs, including Prilosec and Nexium, is estimated to
negatively affect the sales of branded versions. A further decrease is
appearing more with the expected expiration of other patented drugs, such as
Dexilant.
View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market
Get in touch
At Million Insights, we work with
the aim to reach the highest levels of customer satisfaction. Our
representatives strive to understand diverse client requirements and cater to
the same with the most innovative and functional solutions.
No comments:
Post a Comment